blz-945

(S)-BLZ-945 is an enantiomer of BLZ-945 and exhibits inhibitory activity against CSF1R (IC₅₀ = 0.8 nM). BLZ-945 is a selective, potent, and brain-penetrant CSF-1R (c-Fms) inhibitor (IC₅₀ = 1 nM).

Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase homologs.

SB 706504 is an effective p38 MAPK inhibitor that suppresses inflammatory gene expression in macrophages and inhibits TNFα production in LPS-stimulated chronic obstructive pulmonary disease (COPD).

Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable CSF1-R inhibitor with an IC50 of 1 nM, promoting apoptosis in tumor cells and significantly restricting tumor growth in murine models, thereby proving useful in cancer and amyotrophic lateral sclerosis (ALS) studies [1].